TW200745104A - Multikinase inhibitor - Google Patents

Multikinase inhibitor

Info

Publication number
TW200745104A
TW200745104A TW095128727A TW95128727A TW200745104A TW 200745104 A TW200745104 A TW 200745104A TW 095128727 A TW095128727 A TW 095128727A TW 95128727 A TW95128727 A TW 95128727A TW 200745104 A TW200745104 A TW 200745104A
Authority
TW
Taiwan
Prior art keywords
binding site
alkyl
multikinase inhibitor
formula
prodrug
Prior art date
Application number
TW095128727A
Other languages
English (en)
Chinese (zh)
Inventor
Sawako Ozawa
Nobuhiro Oikawa
Eisaku Mizuguchi
Hirosato Ebiike
Fumio Watanabe
Kenji Morikami
Nobuo Shimma
Nobuya Ishii
Toshiyuki Tsukaguchi
Yasuhiro Tamaki
Hidenori Takahashi
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Univ Tokyo filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200745104A publication Critical patent/TW200745104A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW095128727A 2005-08-05 2006-08-04 Multikinase inhibitor TW200745104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005228726 2005-08-05
JP2005347532 2005-12-01

Publications (1)

Publication Number Publication Date
TW200745104A true TW200745104A (en) 2007-12-16

Family

ID=37727321

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095128727A TW200745104A (en) 2005-08-05 2006-08-04 Multikinase inhibitor

Country Status (5)

Country Link
US (1) US8299252B2 (de)
EP (1) EP1921078B1 (de)
JP (1) JP5072595B2 (de)
TW (1) TW200745104A (de)
WO (1) WO2007018137A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070929A1 (de) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
AU2010289143A1 (en) * 2009-08-24 2012-02-16 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2686317A4 (de) * 2011-03-17 2014-08-20 Selexagen Therapeutics Inc Raf-kinase-hemmer
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3638669A1 (de) * 2017-06-13 2020-04-22 Bayer Pharma Aktiengesellschaft Substituierte pyrrolopyridinderivate
WO2018228923A1 (en) * 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
US20200246347A1 (en) * 2017-06-13 2020-08-06 Bayer Pharma Aktiengesellschaft Substituted Pyrrolopyridine-Derivatives
CN115197130B (zh) * 2022-07-27 2023-06-27 安徽医科大学 一种芳基脲类衍生物及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839639D1 (en) 1997-05-23 2008-08-07 Bayer Pharmaceuticals Corp Raf kinase hemmer
EP1056725B1 (de) 1997-12-22 2006-06-07 Bayer Pharmaceuticals Corp. Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
RU2247109C9 (ru) 1997-12-22 2005-06-20 Байер Копэрейшн Симметричные и несимметричные производные дифенилмочевины (варианты), фармацевтическая композиция, способ подавления роста опухолевых клеток, опосредованного киназой raf
CZ299156B6 (cs) 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
PT1415987E (pt) * 2000-10-20 2007-05-31 Eisai R&D Man Co Ltd Compostos contendo aneis aromáticos azotados utilizados como agentes anti-cancerígenos.
ES2283543T3 (es) 2001-04-20 2007-11-01 Bayer Pharmaceuticals Corporation Inhibicion de raf kinasa usando quinolil-, isoquinolil- o piridil ureas.
US20030138627A1 (en) 2001-11-02 2003-07-24 Finlayson Malcolm F. Molecular melt and methods for making and using the molecular melt
US6740413B2 (en) 2001-11-05 2004-05-25 3M Innovative Properties Company Antistatic compositions
ES2275931T5 (es) 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US20050197371A1 (en) * 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds

Also Published As

Publication number Publication date
EP1921078A1 (de) 2008-05-14
US20100168430A1 (en) 2010-07-01
EP1921078B1 (de) 2013-01-09
EP1921078A4 (de) 2011-02-23
WO2007018137A1 (ja) 2007-02-15
JP5072595B2 (ja) 2012-11-14
JPWO2007018137A1 (ja) 2009-02-19
US8299252B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
TW200745104A (en) Multikinase inhibitor
TW200612920A (en) Novel imidazolidine derivatives
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
TN2010000091A1 (en) Substituted pyrazole derivative
MX344669B (es) Agente antiplaquetas novedoso.
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
TW200642683A (en) Heterocyclic compound
WO2008108386A1 (ja) 医薬組成物
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
TW200621759A (en) Novel aminopyridine derivatives having aurora A selective inhibitory action
CA2616580A1 (en) Macrocyclic inhibitors of hepatitis c virus
EP1724262A4 (de) 1-(2h)-isochinolonderivat
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
TW200732284A (en) Amine compound and pharmaceutical use thereof
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
UA88329C2 (en) Dna-pk inhibitors
WO2008155668A3 (en) Heteroarylamide pyrimidone compounds
RS20050182A (en) Derivatives of dioxane-2-alkyl carbamates,preparation method thereof and application of same in therapeutics
EP1741714A4 (de) Heterocyclische verbindung und mittel gegen maligne tumore, das diese enthält
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
JO2808B1 (en) Compounds and their preparation and pharmaceutical compounds
WO2009063990A1 (ja) ベンズアゼピノン化合物
TW200637807A (en) Norvaline derivative and method for preparation thereof